This page includes links to articles highlighting the top hematologic cancer research published on Cancer Therapy Advisor in ...
Olverembatinib demonstrated activity in patients with CP-CML who received first- or second-generation TKIs as first-line therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback